Pharmaceutical Executive January 14, 2022
Pharma R&D return on investment rises to highest level since 2014.
The report shows a rise in peak sales, reduced cost of development, and reduced length of cycle times, which collectively, indicate that pharma companies are starting to see the benefits of optimized processes from previous years and innovative changes to the R&D process. The COVID-19 vaccine development process may serve as a blueprint for the industry to plan, design and execute studies more efficiently across R&D portfolios.
Deloitte’s...
Today's Sponsors
Today's Sponsor